Guardant’s Cancer Blood Test Matches Tissue Biopsies in TrialBy
A large-scale study comparing Guardant Health Inc.’s blood test to tissue biopsies showed that results were closely matched. The findings may help doctors feel more confident in using the blood test as a non-invasive alternative to traditional biopsies, according to the startup.
To continue reading this article you must be a Bloomberg Professional Service Subscriber.
If you believe that you may have received this message in error please let us know.
- Bitcoin Futures Deliver Wild Ride as Debut Brings Rally, Halts
- Investors Told to Brace for Steepest Rate Hikes Since 2006
- World's Second-Tallest Building Opens With a Whimper After Delay
- A Manager of $42 Billion Fears Bubble in World's Biggest Stocks
- Longtime NPR Host Tom Ashbrook Is Facing Misconduct Allegations